• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病作为艰难梭菌感染的住院炎症性肠病患者死亡率的预测因素

Chronic Kidney Disease as a Predictor of Mortality in Hospitalized Inflammatory Bowel Disease Patients With Clostridioides difficile Infection.

作者信息

Sleiman Joelle, Gaballa Andrew, Aslam Taimur, Rizvi Taqi A, El Sayegh Suzanne

机构信息

Internal Medicine, Staten Island University Hospital, New York City, USA.

Internal Medicine, State University of New York Downstate Health Sciences University, New York City, USA.

出版信息

Cureus. 2025 Jul 16;17(7):e88113. doi: 10.7759/cureus.88113. eCollection 2025 Jul.

DOI:10.7759/cureus.88113
PMID:40821332
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12356687/
Abstract

Introduction Clostridioides difficile infection (CDI) leads to significant morbidity and mortality in hospitalized patients. We aim to investigate whether chronic kidney disease (CKD) or end-stage renal disease (ESRD) are predictors of mortality in admitted patients with CDI, and whether the presence of inflammatory bowel disease (IBD) has any impact on the mortality rate.  Methods The data of 133,099 hospitalized patients with CDI were analyzed from the National Inpatient Sample (NIS) database from 2016 to 2018. Baseline risk factors were identified using ICD-10 codes. Propensity score matching was used to match CKD/ESRD patients with patients without kidney disease based on age, gender, and IBD status (Crohn's disease or ulcerative colitis). A multivariable logistic regression model was used to establish the relationship between variables and adjusted for underlying risk factors. The primary endpoint was all-cause mortality among hospitalized patients with CDI, particularly those with IBD. Results Our cohort included 133,099 hospitalized patients with CDI, among whom 20,700 (15.6%) had CKD, 12,178 (9.1%) had ESRD, and 6104 (4.6%) had IBD. The mean age was 74, 63, and 63 years (p<0.001) in patients with CKD, ESRD, and those without kidney disease, respectively. CDI patients with ESRD had a higher proportion of males (6095, 50.3%), compared to those with CKD and without kidney disease (9494, 45.9%, and 40,876, 40.8%, respectively; p<0.001). Propensity score matching was performed, and the patients were matched on age, resulting in a 1:1 exact match for 32,878 patients. Logistic regression analysis showed that in CDI patients with IBD, CKD was associated with a statistically insignificant trend towards a higher all-cause mortality rate as compared to CDI patients without IBD (odds ratio, 1.682 vs odds ratio, 1.229, p>0.05). However, ESRD patients had a significantly higher all-cause mortality rate (Odds ratio, 3.738, 95% CI 2.175-6.425) among hospitalized CDI patients with IBD compared to those without IBD (odds ratio, 1.612, 95% CI 1.486-1.749) (p<0.05). Conclusion Kidney disease, particularly ESRD, is associated with a significant increase in mortality in CDI patients with IBD compared to those without IBD. These findings highlight the importance of aggressive CDI management in patients with IBD and ESRD.

摘要

引言 艰难梭菌感染(CDI)会导致住院患者出现严重的发病率和死亡率。我们旨在调查慢性肾脏病(CKD)或终末期肾病(ESRD)是否为CDI住院患者死亡率的预测因素,以及炎症性肠病(IBD)的存在是否对死亡率有任何影响。方法 分析了2016年至2018年国家住院患者样本(NIS)数据库中133,099例CDI住院患者的数据。使用国际疾病分类第十版(ICD-10)编码确定基线风险因素。倾向评分匹配用于根据年龄、性别和IBD状态(克罗恩病或溃疡性结肠炎)将CKD/ESRD患者与无肾脏疾病的患者进行匹配。使用多变量逻辑回归模型建立变量之间的关系,并对潜在风险因素进行校正。主要终点是CDI住院患者的全因死亡率,特别是那些患有IBD的患者。结果 我们的队列包括133,099例CDI住院患者,其中20,700例(15.6%)患有CKD,12,178例(9.1%)患有ESRD,6104例(4.6%)患有IBD。CKD患者、ESRD患者和无肾脏疾病患者的平均年龄分别为74岁、63岁和63岁(p<0.001)。与CKD患者和无肾脏疾病的患者相比,ESRD的CDI患者男性比例更高(分别为6095例,50.3%;9494例,45.9%;40,876例,40.8%;p<0.001)。进行了倾向评分匹配,患者按年龄匹配,32,878例患者实现了1:1精确匹配。逻辑回归分析表明,在患有IBD的CDI患者中,与没有IBD的CDI患者相比,CKD与全因死亡率升高呈统计学上无显著意义的趋势相关(比值比,1.682对1.229,p>0.05)。然而,与没有IBD的住院CDI患者相比(比值比,1.612,95%置信区间1.486-1.749),患有IBD的住院CDI患者中ESRD患者的全因死亡率显著更高(比值比,3.738,95%置信区间2.175-6.425)(p<0.05)。结论 与没有IBD的患者相比,患有IBD的CDI患者中,肾脏疾病,尤其是ESRD,与死亡率显著增加相关。这些发现凸显了对患有IBD和ESRD的患者积极管理CDI的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efa4/12356687/9c278cfed233/cureus-0017-00000088113-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efa4/12356687/9c278cfed233/cureus-0017-00000088113-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efa4/12356687/9c278cfed233/cureus-0017-00000088113-i01.jpg

相似文献

1
Chronic Kidney Disease as a Predictor of Mortality in Hospitalized Inflammatory Bowel Disease Patients With Clostridioides difficile Infection.慢性肾脏病作为艰难梭菌感染的住院炎症性肠病患者死亡率的预测因素
Cureus. 2025 Jul 16;17(7):e88113. doi: 10.7759/cureus.88113. eCollection 2025 Jul.
2
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study.维多珠单抗治疗的炎症性肠病患者的医疗资源利用和生产损失:瑞典前瞻性多中心SVEAH研究的结果
Therap Adv Gastroenterol. 2025 Jul 17;18:17562848251352023. doi: 10.1177/17562848251352023. eCollection 2025.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Patient education interventions for the management of inflammatory bowel disease.炎症性肠病管理的患者教育干预措施。
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013854. doi: 10.1002/14651858.CD013854.pub2.
5
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
6
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.干预措施用于克罗恩病和炎症性肠病的腹痛管理。
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.
7
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌(艰难梭菌)。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
8
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.用于预防成人和儿童艰难梭菌相关性腹泻的益生菌
Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4.
9
RECOVID: Retrospective Observational Study of Renal Outcomes and Long-Term Mortality in Patients With COVID-19-Associated AKI, A Comparison Between Vaccinated and Unvaccinated Patients.RECOVID:COVID-19相关性急性肾损伤患者肾脏结局和长期死亡率的回顾性观察研究,接种疫苗与未接种疫苗患者的比较
Kidney Med. 2025 Jun 18;7(7):101020. doi: 10.1016/j.xkme.2025.101020. eCollection 2025 Jul.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

本文引用的文献

1
Concurrent chronic kidney disease in patients with inflammatory bowel disease, a systematic review and meta-analysis.炎症性肠病患者并发慢性肾脏病的系统评价与Meta分析
Front Med (Lausanne). 2024 Oct 3;11:1485087. doi: 10.3389/fmed.2024.1485087. eCollection 2024.
2
Diagnosis and Management of Clostridioides difficile in Inflammatory Bowel Disease.炎症性肠病中艰难梭菌的诊断与管理
Am J Gastroenterol. 2025 Feb 1;120(2):313-319. doi: 10.14309/ajg.0000000000003076. Epub 2024 Sep 4.
3
Chronic Kidney Disease in Inflammatory Bowel Disease: a Systematic Review and Meta-analysis.
炎症性肠病中的慢性肾脏病:系统评价和荟萃分析。
J Crohns Colitis. 2024 Sep 3;18(9):1464-1475. doi: 10.1093/ecco-jcc/jjae049.
4
Altered Expression of Intestinal Tight Junctions in Patients with Chronic Kidney Disease: A Pathogenetic Mechanism of Intestinal Hyperpermeability.慢性肾脏病患者肠道紧密连接的表达改变:肠道通透性增加的发病机制
Biomedicines. 2024 Feb 5;12(2):368. doi: 10.3390/biomedicines12020368.
5
A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States.美国艰难梭菌感染的危险因素及发生时间的系统文献综述
Infect Dis Ther. 2024 Feb;13(2):273-298. doi: 10.1007/s40121-024-00919-0. Epub 2024 Feb 13.
6
Inflammatory bowel disease and infection: clinical presentation, diagnosis, and management.炎症性肠病与感染:临床表现、诊断及管理
Therap Adv Gastroenterol. 2023 Nov 28;16:17562848231207280. doi: 10.1177/17562848231207280. eCollection 2023.
7
Kidney Biopsy Findings and Clinical Outcomes of US Veterans with Inflammatory Bowel Disease.美国退伍军人炎症性肠病的肾活检结果及临床结局
Glomerular Dis. 2023 Sep 30;3(1):233-240. doi: 10.1159/000534062. eCollection 2023 Jan-Dec.
8
Clostridium difficile in inflammatory bowel disease.艰难梭菌与炎症性肠病。
Curr Opin Gastroenterol. 2023 Jul 1;39(4):257-262. doi: 10.1097/MOG.0000000000000949. Epub 2023 May 15.
9
Strategies to prevent infections in acute-care hospitals: 2022 Update.急性护理医院预防感染的策略:2022年更新版
Infect Control Hosp Epidemiol. 2023 Apr;44(4):527-549. doi: 10.1017/ice.2023.18.
10
Renal and Urological Disorders Associated With Inflammatory Bowel Disease.与炎症性肠病相关的肾脏和泌尿系统疾病。
Inflamm Bowel Dis. 2023 Aug 1;29(8):1306-1316. doi: 10.1093/ibd/izac140.